UGRO CAPITAL COMPLETES ACQUISITION OF PROFECTUS CAPITAL

▴ UGRO Capital
A HIGHLY ACCRETIVE TRANSACTION DESIGNED TO MAXIMIZE SHAREHOLDER VALUE.
 
Hyderabad, December 08, 2025: UGRO Capital Limited (NSE: UGROCAP | BSE: 511742), a leading DataTech NBFC focused on MSME lending, today announced the completion of its 100% acquisition of Profectus Capital, marking one of the most value-accretive transactions in its journey to build India’s leading MSME lending institution, strengthening scale, profitability, capital productivity, and return ratios, and positioning the company for accelerated earnings growth over the next several years.
 
With the addition of Profectus ₹3,468 crore AUM, UGRO’s consolidated AUM rises to ₹15,471 crore, a consolidated 29% AUM expansion. The acquisition materially strengthens the company’s fundamentals through an immediate ₹150 crore annualized profit accretion, achieved with zero origination cost and delivered on Day 1. The integration unlocks an additional ₹115 crore in operating synergies, expanding margins and driving a 60–70 bps improvement in ROA, thereby accelerating UGRO’s path toward stronger long-term ROE. With a significant shift to a 75% secured asset mix, the combined entity benefits from greater earnings stability and lower credit-cost volatility, key drivers of sustainable valuation growth. The transaction represents highly efficient deployment of UGRO’s recent equity rise into a fully secured, high-yield asset base that is accretive to capital adequacy and enhances the profitability per unit of capital deployed. In addition, Profectus established lender relationships to strengthen UGRO’s liability franchise, supporting better funding costs and incremental spread improvement. The deal also opens a new ₹2,000 crore medium-term opportunity in school financing, expanding UGRO’s future profit pools and further diversifying earnings. With the acquisition now complete, UGRO is poised to deliver stronger EPS growth, improved return ratios, and superior long-term value for its shareholders.
 
Profectus now becomes a wholly owned subsidiary of UGRO Capital effective December 8, 2025. The company will soon initiate the merger process of Profectus into the parent company, subject to Board and shareholder approvals. Both companies will continue operating independently until formal approval of the merger.
 
Commenting on the completion, Mr. Shachindra Nath, Founder and Managing Director of UGRO Capital said, “With the completion of this acquisition, we have strengthened the foundation for the next phase of UGRO’s growth, one that is defined by stronger returns, more efficient use of capital and a sharper, more resilient earnings engine. Profectus brings a secured, high-quality book that immediately enhances our profitability profile, but more importantly, it gives us long-run compounding power through a better asset mix, deeper distribution and a more diversified lender base. This transaction is an investment in stability, scalability and value creation, and sets us firmly on the path to delivering consistently higher ROE for our shareholders.”
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Clinical Interventions in Chronic Hepatitis B and C: Antiviral Efficacy, Liver Fibrosis Scoring, and Monitoring August 11, 2026
Common Health Mistakes Indians Should Avoid: A Practical Guide to Everyday WellnessAugust 11, 2026
How to Build a Healthy Lifestyle After 40: A Practical Guide for Indian AdultsAugust 11, 2026
Milk Microbiome Could Hold New Clues to Lifelong Health, Experts SayAugust 10, 2026
Globally Renowned Dermatologist and Sesderma Founder Professor Dr. Gabriel Serrano to Visit India to Showcase Cutting-Edge Derma-Tech for Indian Skincare at Scientific Symposiums Hosted by Iberia PharmaceuticalsAugust 10, 2026
Sharda Hospital Celebrates World Breastfeeding Week with a Week-Long Awareness ProgrammeAugust 10, 2026
Swinburne University of Technology Opens Applications for Master of Engineering ScienceAugust 10, 2026
GLP-1 Receptor Agonists: A New Era in Weight Loss TreatmentAugust 10, 2026
Immunotherapy vs. Chemotherapy: Understanding the Mechanisms of Precision OncologyAugust 10, 2026
Mitigating Tech-Induced Ailments: Managing Screen Time, Sedentary Lifestyles, and Dry Eye SyndromeAugust 10, 2026
The Blueprint of Validation: Navigating Medical AI’s "Reckoning Year"August 10, 2026
The Future of Smart Hospitals: Redefining Healthcare Delivery in India August 10, 2026
Healthcare Data Security in India: Risks, Threats, and Best Practices for a Digital-First Health EcosystemAugust 10, 2026
The Science of Resilience: Psychological Strategies for Modern StressAugust 08, 2026
The Science of Fasting: 2026 Research on Autophagy and LongevityAugust 08, 2026
Early Markers of Insulin Resistance: Moving Beyond Fasting Blood SugarAugust 08, 2026
Healthcare Management Challenges in India: What Hospital Leaders Must Address NowAugust 08, 2026
Importance of Patient Safety: Why Every Hospital in India Must Prioritize ItAugust 08, 2026
Decoding Fatty Liver Disease: Symptoms, Reversibility, and the MASLD/NAFLD SpectrumAugust 07, 2026
Heart-Healthy Dietary Patterns: Translating Clinical Nutrition Guidelines into Daily MealsAugust 07, 2026